PepGen Inc. is a clinical-stage biopharmaceutical company developing oligonucleotide therapeutics using its Enhanced Delivery Oligonucleotide (EDO) platform. Its lead product candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1). The company has conducted two Phase 1 and three Phase 2 clinical trials since inception. PepGen has no approved products and has not generated revenue from product sales.
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001193125-26-091536 | EDGAR | 107K words |
| 2025-02-24 | 2024-12-31 | 0000950170-25-025226 | EDGAR | 108K words |
| 2024-03-06 | 2023-12-31 | 0000950170-24-027178 | EDGAR | 108K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009500 | EDGAR | 115K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336754 | EDGAR | 75K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-276001 | EDGAR | 75K words |
| 2025-08-07 | 2025-06-30 | 0001193125-25-174979 | EDGAR | 75K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066414 | EDGAR | 74K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122821 | EDGAR | 72K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093351 | EDGAR | 71K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059519 | EDGAR | 69K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060702 | EDGAR | 74K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039392 | EDGAR | 73K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020829 | EDGAR | 69K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024186 | EDGAR | 72K words |
| 2022-08-12 | 2022-06-30 | 0000950170-22-017013 | EDGAR | 71K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-336767 | EDGAR | 2K words |
| 2026-03-30 | 0001193125-26-131786 | EDGAR | 1K words |
| 2026-03-04 | 0001193125-26-091784 | EDGAR | 3K words |
| 2026-03-04 | 0001193125-26-091503 | EDGAR | 3K words |
| 2025-12-08 | 0001193125-25-310544 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-276019 | EDGAR | 2K words |
| 2025-11-07 | 0001193125-25-271089 | EDGAR | 1K words |
| 2025-10-01 | 0001193125-25-226746 | EDGAR | 2K words |
| 2025-09-26 | 0001193125-25-218503 | EDGAR | 1K words |
| 2025-09-24 | 0001193125-25-215435 | EDGAR | 2K words |
92 total filings indexed. 66 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001835597 |
| Ticker | PEPG |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pepgen.com |
| Listed | 2022-05-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PEPG (~200 tokens, structured JSON with cryptographic provenance)